BR112017017594A2 - dosagens de panobinostat para mieloma múltiplo - Google Patents

dosagens de panobinostat para mieloma múltiplo

Info

Publication number
BR112017017594A2
BR112017017594A2 BR112017017594-0A BR112017017594A BR112017017594A2 BR 112017017594 A2 BR112017017594 A2 BR 112017017594A2 BR 112017017594 A BR112017017594 A BR 112017017594A BR 112017017594 A2 BR112017017594 A2 BR 112017017594A2
Authority
BR
Brazil
Prior art keywords
panobinostat
multiple myeloma
dosages
bortezomib
safety
Prior art date
Application number
BR112017017594-0A
Other languages
English (en)
Inventor
Lin Rong
Mu Song
Paul Sofia
GRAZIOLI Laura
Capdeville Renaud
Binlich Florence
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017017594(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017017594A2 publication Critical patent/BR112017017594A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a presente invenção refere-se a tratamento de mieloma múltiplo usando uma combinação de panobinostat e bortezomib com doses especificadas ajustadas para segurança.
BR112017017594-0A 2015-02-19 2016-02-17 dosagens de panobinostat para mieloma múltiplo BR112017017594A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US62/118,254 2015-02-19
US201562119571P 2015-02-23 2015-02-23
US62/119,571 2015-02-23
PCT/IB2016/050850 WO2016132303A1 (en) 2015-02-19 2016-02-17 Panobinostat dosages for multiple myeloma

Publications (1)

Publication Number Publication Date
BR112017017594A2 true BR112017017594A2 (pt) 2018-05-08

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017594-0A BR112017017594A2 (pt) 2015-02-19 2016-02-17 dosagens de panobinostat para mieloma múltiplo

Country Status (19)

Country Link
US (3) US20190388393A1 (pt)
EP (1) EP3258933A1 (pt)
JP (2) JP2018507216A (pt)
KR (1) KR20170118798A (pt)
CN (1) CN107249596A (pt)
AU (2) AU2016221327A1 (pt)
BR (1) BR112017017594A2 (pt)
CA (1) CA2976755A1 (pt)
CL (1) CL2017002116A1 (pt)
IL (1) IL253895A0 (pt)
MA (1) MA41544A (pt)
MX (1) MX2017010577A (pt)
PH (1) PH12017501494A1 (pt)
RU (1) RU2729425C2 (pt)
SG (1) SG11201706521XA (pt)
TN (1) TN2017000356A1 (pt)
TW (1) TW201630602A (pt)
WO (1) WO2016132303A1 (pt)
ZA (1) ZA201705363B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1912640E (pt) * 2005-08-03 2015-09-22 Novartis Ag Uso do inibidor da hdac panobinostat para o tratamento do mieloma
ES2570934T3 (es) 2006-06-12 2016-05-23 Novartis Ag Sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida
AU2008216327A1 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
MX2015011733A (es) * 2013-03-14 2016-04-25 Pharmacyclics Llc Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4.

Also Published As

Publication number Publication date
WO2016132303A1 (en) 2016-08-25
US20200093795A1 (en) 2020-03-26
RU2017132445A (ru) 2019-03-20
TW201630602A (zh) 2016-09-01
EP3258933A1 (en) 2017-12-27
JP2021105048A (ja) 2021-07-26
CL2017002116A1 (es) 2018-05-18
US20190388393A1 (en) 2019-12-26
ZA201705363B (en) 2019-07-31
AU2019200876B2 (en) 2020-05-28
CN107249596A (zh) 2017-10-13
JP2018507216A (ja) 2018-03-15
MA41544A (fr) 2017-12-26
TN2017000356A1 (en) 2019-01-16
AU2019200876A1 (en) 2019-02-28
IL253895A0 (en) 2017-10-31
AU2016221327A1 (en) 2017-08-31
KR20170118798A (ko) 2017-10-25
RU2017132445A3 (pt) 2019-09-23
US20230181529A1 (en) 2023-06-15
CA2976755A1 (en) 2016-08-25
RU2729425C2 (ru) 2020-08-06
PH12017501494A1 (en) 2018-01-29
SG11201706521XA (en) 2017-09-28
MX2017010577A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018000429A1 (es) Moduladores de la expresión de kras
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CL2017001046A1 (es) Inhibidoes del bromodominio
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
TW201713333A (en) Methods of treating a neurodegenerative disease
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112017010440A2 (pt) administração sublingual de riluzol
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112017008481A2 (pt) composto antimicótico
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CR20170005A (es) Derivados de insoindolina
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2618 DE 09-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]